An Expert Report on Dimethyl Fumarate (DB08908)

Executive Summary

Dimethyl fumarate (DMF) is a pleiotropic oral immunomodulatory agent with established efficacy in the treatment of relapsing forms of multiple sclerosis (MS) and moderate-to-severe plaque psoriasis. Classified as a small molecule, it is the methyl ester of fumaric acid, a compound with historical roots in herbal medicine. Its therapeutic effects are attributed to a complex and multifactorial mechanism of action that is not yet fully elucidated. The primary pathways involve the activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway, which confers cytoprotective effects against oxidative stress, and the inhibition of the pro-inflammatory Nuclear Factor-kappa B (NF-κB) pathway. This dual action results in a systemic shift from a pro-inflammatory to an anti-inflammatory immune cell phenotype, reducing autoimmune-mediated damage.

In the treatment of MS, marketed as Tecfidera®, pivotal Phase 3 clinical trials (DEFINE and CONFIRM) demonstrated that DMF significantly reduces the annualized relapse rate, delays the progression of physical disability, and markedly decreases MRI lesion activity when compared with placebo. For moderate-to-severe plaque psoriasis, marketed as Skilarence® in the European Union, the pivotal Phase 3 BRIDGE trial established its non-inferiority to a mixed fumaric acid ester formulation and its superiority to placebo in achieving significant skin clearance, as measured by the Psoriasis Area and Severity Index (PASI).

Pharmacokinetically, DMF is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract and blood to its active metabolite, monomethyl fumarate (MMF). A key clinical feature is that its metabolism does not involve the cytochrome P450 (CYP) enzyme system, which minimizes the potential for many common drug-drug interactions. The safety and tolerability profile of DMF is well-characterized. The most common adverse events are flushing and gastrointestinal disturbances, which are typically most pronounced upon treatment initiation and are generally manageable. However, DMF carries significant safety concerns that require diligent clinical monitoring. These include the potential to cause lymphopenia, which in turn increases the risk of rare but serious opportunistic infections, most notably Progressive Multifocal Leukoencephalopathy (PML). The potential for drug-induced liver injury also necessitates baseline and periodic monitoring of liver function.

In conclusion, dimethyl fumarate represents a valuable and established oral therapy for two distinct chronic autoimmune diseases. It offers a unique mechanism of action that balances immunomodulation with cytoprotection. Its place in therapy is well-defined as an effective option for a broad range of patients, though its use requires careful patient selection, education on managing common side effects, and strict adherence to safety monitoring protocols to mitigate its more serious risks.

1.0 Introduction and Historical Context

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid, an organic compound named after the plant Fumaria officinalis (commonly known as earth smoke), where it occurs naturally.[1] It is a small molecule drug classified as an immunomodulatory, anti-inflammatory, and cytoprotective agent.[2] Its journey from a component of a traditional remedy to a precisely formulated monotherapy for distinct autoimmune diseases illustrates a significant evolution in pharmaceutical development.

The therapeutic use of fumaric acid esters (FAEs) began in Germany, where a proprietary mixture containing DMF and three salts of monoethyl fumarate (MEF) was developed. This combination product, branded as Fumaderm®, was licensed in Germany in 1994 and became an established first-line oral therapy for adults with moderate-to-severe psoriasis.[1] The efficacy of this mixture was based on empirical evidence, and for many years, it was a cornerstone of psoriasis treatment in Germany, providing a foundation of long-term clinical and safety experience with this class of compounds.[3]

Subsequent scientific investigation sought to dissect the components of the Fumaderm® mixture to identify the principal active agent. This research ultimately revealed that DMF, via its rapid conversion to the active metabolite monomethyl fumarate (MMF), was the primary driver of the therapeutic effect.[3] This crucial understanding paved the way for the development of a more refined, single-agent therapy. This led to the creation of Skilarence®, an oral formulation containing only DMF, which was approved by the European Medicines Agency (EMA) in 2017 for the treatment of moderate-to-severe plaque psoriasis in adults.[1] Clinical trials successfully demonstrated that this monotherapy was non-inferior to the original Fumaderm® mixture, confirming that the other FAE salts were not essential for efficacy.[4]

In parallel with its development for psoriasis, the immunomodulatory and newly discovered neuroprotective properties of DMF made it an attractive candidate for the treatment of multiple sclerosis (MS), a mechanistically distinct autoimmune disease of the central nervous system.[7] This line of research culminated in the U.S. Food and Drug Administration (FDA) approval of DMF, branded as Tecfidera®, on March 27, 2013, for the treatment of adults with relapsing forms of MS.[9] Tecfidera® was the third oral disease-modifying therapy (DMT) to be approved for MS, following fingolimod and teriflunomide, offering patients a convenient alternative to injectable treatments.[2]

Separate from its medical applications, DMF was also used commercially as a biocide. It was placed in sachets within consumer goods such as furniture and shoes to prevent the growth of mold during transport and storage in humid climates.[1] This application led to a significant public health issue due to reports of severe allergic contact dermatitis in consumers who came into contact with these products, an incident that became widely known as the "poison chair" controversy.[1] DMF was identified as an extremely potent contact sensitizer, capable of inducing severe eczema at very low concentrations.[1] As a result, the European Union banned the manufacture of consumer products containing DMF in 1998 and prohibited their importation in 2009.[1] This potent sensitizing property is a key reason why DMF is not formulated as a topical treatment for psoriasis, necessitating an oral route of administration and acceptance of its systemic risk profile to achieve dermatological benefits.[12]

2.0 Physicochemical Properties and Formulations

Dimethyl fumarate is a simple diester molecule with a well-defined chemical structure and set of physical properties. It is formally the product of the condensation of both carboxylic acid groups of fumaric acid with methanol.[11] Its chemical and physical characteristics are fundamental to its formulation, stability, and biological activity.

The compound is identified by the IUPAC name Dimethyl (2E)-but-2-enedioate.[1] It is also known by several synonyms, including (E)-But-2-enedioic acid dimethyl ester, Dimethyl trans-ethylenedicarboxylate, and Fumaric acid, dimethyl ester.[1] For unambiguous identification in scientific and regulatory databases, it is assigned a unique Chemical Abstracts Service (CAS) Number of 624-49-7.[1]

Physically, DMF is a white to almost-white crystalline powder at room temperature.[13] It has a molecular formula of

C6​H8​O4​ and an average molecular weight of approximately 144.13 g/mol.[2] It exhibits a melting point in the range of 103 to 105 °C.[13] Its solubility profile is characterized by being insoluble in water but soluble in organic solvents such as acetone and chloroform.[13]

To prevent irritation of the stomach lining and ensure delivery to the small intestine for optimal absorption, DMF is formulated for oral use in delayed-release (also known as gastro-resistant) capsules or tablets.[14] This formulation protects the parent drug from the acidic environment of the stomach, allowing it to pass into the more alkaline milieu of the small intestine where it is hydrolyzed and absorbed.[17]

Table 1: Key Identifiers and Physicochemical Properties of Dimethyl Fumarate

Property/Identifier	Value	Source(s)
Common Name	Dimethyl fumarate	1
IUPAC Name	Dimethyl (2E)-but-2-enedioate	1
CAS Number	624-49-7	1
DrugBank ID	DB08908	1
PubChem CID	637568	1
UNII	FO2303MNI2	1
Molecular Formula	C6​H8​O4​	2
Average Molecular Weight	144.13 g/mol	2
Appearance	White to almost white powder to crystal	13
Solubility	Insoluble in water; soluble in acetone, chloroform	13
Melting Point	103.0 - 105.0 °C	13

3.0 Mechanism of Action: A Pleiotropic Immunomodulator

The mechanism of action of dimethyl fumarate is complex, multifactorial, and not yet fully understood, reflecting its pleiotropic nature—the ability to produce multiple distinct effects through various cellular pathways.[11] Its therapeutic benefits in both multiple sclerosis and psoriasis are thought to derive from a unique combination of antioxidant, cytoprotective, and immunomodulatory activities.[2] These effects are mediated through both Nrf2-dependent and Nrf2-independent pathways.[8]

3.1 Nrf2-Dependent Pathway: The Antioxidant and Cytoprotective Axis

A central and well-established component of DMF's mechanism is the activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway.[7] Nrf2 is a key regulator of the cellular response to oxidative stress. Under normal conditions, Nrf2 is kept inactive in the cytoplasm by its inhibitor, Kelch-like ECH-associated protein 1 (Keap1), which targets Nrf2 for degradation.[2]

DMF and its active metabolite, MMF, are electrophilic compounds that can form a Michael addition reaction with cysteine residues on Keap1.[19] This covalent modification of Keap1 prevents it from binding to and degrading Nrf2. As a result, Nrf2 becomes stabilized, accumulates in the cytoplasm, and translocates to the nucleus.[19] Once in the nucleus, Nrf2 binds to a specific DNA sequence known as the Antioxidant Response Element (ARE) in the promoter region of target genes. This binding initiates the transcription of a broad array of antioxidant and cytoprotective genes, including heme oxygenase-1 (HO-1) and enzymes critical for the synthesis of glutathione (GSH).[19]

This upregulation of the body's endogenous antioxidant defenses is believed to be a crucial mechanism, particularly in MS, where oxidative stress is a key contributor to neuronal and oligodendrocyte damage.[7] By enhancing the ability of CNS cells to withstand oxidative insults, DMF exerts neuroprotective and cytoprotective effects.[7]

3.2 Nrf2-Independent Pathways: The Anti-Inflammatory Axis

While the Nrf2 pathway explains the cytoprotective effects of DMF, its profound immunomodulatory actions are also mediated through several Nrf2-independent mechanisms.

3.2.1 Inhibition of the NF-κB Pathway

DMF has been shown to inhibit the Nuclear Factor-kappa B (NF-κB) pathway, a pivotal transcription factor that controls the expression of numerous pro-inflammatory genes, including cytokines, chemokines, and adhesion molecules.[2] By suppressing the activation of NF-κB, DMF effectively dampens the inflammatory cascade that drives the autoimmune pathology in both MS and psoriasis.[22] This leads to a reduction in the production of pro-inflammatory cytokines and a less aggressive immune response.[22]

3.2.2 Modulation of Immune Cell Phenotype and Trafficking

DMF directly alters the composition, function, and trafficking of peripheral immune cells.[2] It induces a systemic shift from a pro-inflammatory immune state to a more anti-inflammatory one. This is achieved through several actions:

• T-Cell Polarization: It promotes a shift in T-helper (Th) cell differentiation away from the pro-inflammatory Th1 and Th17 phenotypes, which are pathogenic in MS and psoriasis, and towards an anti-inflammatory Th2 cell phenotype.[8]
• Reduced CNS Infiltration: In the context of MS, DMF reduces the infiltration of pathogenic lymphocytes, particularly cytotoxic and effector T cells, across the blood-brain barrier and into the central nervous system.[2] This is a critical step in preventing the formation of new inflammatory lesions.
• Myeloid Cell Differentiation: DMF influences myeloid cells, promoting the differentiation of anti-inflammatory type II myeloid cells, which can further help to resolve inflammation.[8]

3.2.3 Other Potential Mechanisms

Emerging research suggests additional mechanisms may contribute to DMF's effects. It has been identified as an in vitro agonist of the nicotinic acid receptor HCA2 (also known as GPR109A), which is expressed on various immune cells.[18] Furthermore, some studies suggest that DMF may inhibit certain ubiquitin-conjugating enzymes (E2 enzymes), thereby interfering with protein regulation downstream of immune-activating Toll-like receptors (TLRs).[23] It may also influence the cellular process of autophagy.[19]

The dual action of DMF—simultaneously activating the protective Nrf2 pathway and suppressing the inflammatory NF-κB pathway—provides a compelling explanation for its unique therapeutic profile. This allows the drug not just to reduce inflammation (preventing relapses in MS and clearing plaques in psoriasis) but also to protect the target tissues (neurons and skin cells) from damage. This multifaceted mechanism distinguishes DMF from many other therapies that may have a more singular mode of action.

However, the clinical description of DMF as an "immunomodulator without causing significant immunosuppression" [13] warrants careful consideration. While the drug's mechanism involves recalibrating the immune system rather than broad cytotoxicity, it demonstrably causes lymphopenia (a reduction in lymphocyte counts) in a subset of patients.[2] This reduction in lymphocytes is a direct immunosuppressive effect and is the primary risk factor for the rare but life-threatening opportunistic infection, Progressive Multifocal Leukoencephalopathy (PML).[27] This highlights that the line between immunomodulation and immunosuppression is not absolute. DMF modulates the immune system, but this modulation can cross a threshold into clinically significant immunosuppression, which constitutes the drug's main safety liability and necessitates rigorous risk management protocols.

4.0 Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

4.1 Pharmacokinetics

The pharmacokinetic profile of dimethyl fumarate is unique and directly influences its clinical use, efficacy, and tolerability. A defining feature is that DMF is a prodrug.[30]

4.1.1 Absorption

Following oral administration of the delayed-release capsule, DMF is rapidly and extensively hydrolyzed by esterases present in the gastrointestinal tract, blood, and tissues to its primary active metabolite, monomethyl fumarate (MMF).[2] Intact DMF is not quantifiable in the plasma after oral dosing; therefore, all pharmacokinetic analyses are based on plasma concentrations of MMF.[2]

The median time to reach peak plasma concentration (Tmax) for MMF is between 2 and 2.5 hours.[2] The exposure to MMF, measured by peak concentration (Cmax) and area under the curve (AUC), increases in a dose-proportional manner over the clinically studied range.[15]

A clinically significant food effect has been observed. Administration with a high-fat, high-calorie meal does not alter the total exposure (AUC) of MMF but decreases the Cmax by 40% and delays the Tmax from approximately 2 hours to 5.5 hours.[15] This blunting of the peak concentration provides the pharmacokinetic rationale for the clinical recommendation to administer DMF with food, as this can reduce the incidence and severity of acute side effects like flushing.[14]

4.1.2 Distribution

The apparent volume of distribution for MMF is moderate, ranging from 53 to 73 liters in healthy subjects.[2] Plasma protein binding of MMF is low to moderate, at 27-45%, and is independent of drug concentration.[2]

4.1.3 Metabolism

A crucial aspect of DMF's pharmacology is its metabolism. The biotransformation of DMF and its active metabolite MMF does not involve the cytochrome P450 (CYP) enzyme system.[2] This is a major clinical advantage, as it signifies a very low potential for pharmacokinetic drug-drug interactions with the vast number of medications that are substrates, inhibitors, or inducers of CYP enzymes. This is particularly relevant for patients with MS and psoriasis, who often have comorbidities requiring polypharmacy.

After its formation, MMF is further metabolized through the endogenous tricarboxylic acid (TCA) cycle, the same fundamental metabolic pathway cells use to generate energy.[2] The ultimate metabolites are common endogenous substances, including fumaric acid, citric acid, glucose, and carbon dioxide.[2]

4.1.4 Excretion

The primary route of elimination for DMF is via exhalation of carbon dioxide (CO2), which accounts for approximately 60% of the administered dose.[2] This is a direct consequence of its metabolism through the TCA cycle. Renal and fecal elimination are minor pathways, accounting for only 16% and 1% of the dose, respectively.[2] Only trace amounts of unchanged MMF are excreted in the urine.[2]

The terminal half-life of MMF is very short, at approximately 1 hour, and the drug does not accumulate in the plasma with repeated twice-daily dosing.[2]

4.2 Pharmacodynamics

The pharmacodynamic effects of DMF are the clinical manifestation of its molecular mechanisms. Preclinical studies confirm that the drug's effects are mediated through both Nrf2-dependent and -independent pathways.[20] Studies in animal models have revealed that these responses are tissue-specific. For instance, MMF (the metabolite of DMF) demonstrates higher penetration into the brain, whereas monoethyl fumarate (a component of the older Fumaderm® mixture) preferentially distributes to the kidney, indicating that different fumarate esters are not pharmacodynamically interchangeable.[32]

The most significant and clinically monitored pharmacodynamic effect is a reduction in peripheral blood lymphocyte counts. In clinical trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment with Tecfidera® and then remained stable.[28] This lymphopenia is a direct on-target effect of the drug's immunomodulatory action and is the primary risk factor for certain serious infections, necessitating routine hematological monitoring.[28] Other pharmacodynamic effects include the documented shift in T-cell populations toward an anti-inflammatory Th2 profile and a reduction in pro-inflammatory cytokine production.[2]

5.0 Clinical Efficacy in Approved Indications

The clinical utility of dimethyl fumarate is firmly established through large, well-controlled clinical trials in two distinct autoimmune diseases: relapsing forms of multiple sclerosis and moderate-to-severe plaque psoriasis.

5.1 Relapsing Forms of Multiple Sclerosis (Tecfidera®)

In neurology, dimethyl fumarate (Tecfidera®) is indicated for the treatment of relapsing forms of multiple sclerosis in adults. This broad indication includes clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS).[2] The approval was primarily based on the positive results from two pivotal, two-year, Phase 3 randomized controlled trials: DEFINE and CONFIRM.[26]

5.1.1 The DEFINE and CONFIRM Trials

The DEFINE (Determination of the Efficacy and safety of oral Fumarate IN relapsing-rEmitting MS) trial enrolled over 1,200 patients with RRMS, comparing DMF 240 mg twice daily (BID) and three times daily (TID) against placebo.[36] The primary endpoint was the proportion of patients who experienced a relapse at two years. The trial met its primary endpoint, with the DMF 240 mg BID group showing a significant reduction in the proportion of patients relapsing (27%) compared to the placebo group (46%).[37] This corresponded to a 53% reduction in the annualized relapse rate (ARR) (0.172 for DMF vs. 0.364 for placebo) and a 38% reduction in the risk of 12-week confirmed disability progression.[36]

The CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) trial enrolled over 1,400 patients with RRMS, comparing DMF 240 mg BID and TID against placebo, and also included an active reference comparator arm of glatiramer acetate (GA) 20 mg daily.[36] The study was not statistically powered for a formal comparison between DMF and GA. The primary endpoint for this trial was the annualized relapse rate at two years. CONFIRM also met its primary endpoint, with DMF 240 mg BID significantly reducing the ARR by 44% compared to placebo (0.224 for DMF vs. 0.401 for placebo).[37] The effect on disability progression in this trial did not reach statistical significance.[39]

5.1.2 MRI Outcomes and Long-Term Efficacy

In addition to clinical outcomes, both trials demonstrated profound and consistent effects on MRI measures of disease activity. Compared to placebo, DMF significantly reduced the number of new or newly enlarging T2-hyperintense lesions by 85% in DEFINE, and the number of gadolinium-enhancing (Gd+) lesions, which indicate active inflammation, by 90% in DEFINE and 74% in CONFIRM.[37] It also reduced the number of new T1-hypointense lesions ("black holes"), thought to represent areas of more severe tissue damage, by 72% in DEFINE.[37]

The long-term efficacy of DMF has been evaluated in the ENDORSE extension study (NCT00835770), which enrolled patients who completed the DEFINE and CONFIRM trials.[36] Data from ENDORSE have shown that the treatment benefits of DMF are strong and sustained, with continued low relapse rates and slowing of disability progression for up to six years of continuous treatment.[36] A key finding from these long-term data is the benefit of early treatment initiation; patients who started on DMF at the beginning of the parent studies had significantly better long-term outcomes, including a 49% lower risk of disability progression at year six, compared to those who were initially on placebo for two years before switching to DMF in the extension phase.[36]

Table 2: Summary of Pivotal Phase 3 Multiple Sclerosis Clinical Trials (DEFINE & CONFIRM)

Feature	DEFINE Study (NCT00420212)	CONFIRM Study (NCT00451451)
Patient Population	>1,200 adults with RRMS	>1,400 adults with RRMS
Treatment Arms (vs. Placebo)	DMF 240 mg BID, DMF 240 mg TID	DMF 240 mg BID, DMF 240 mg TID, Glatiramer Acetate 20 mg QD
Primary Endpoint	Proportion of patients relapsing at 2 years	Annualized Relapse Rate (ARR) at 2 years
ARR Reduction vs. Placebo (BID)	53% (p<0.0001)	44% (p<0.0001)
Disability Progression Reduction	38% reduction in risk (12-week confirmed)	Not statistically significant
Gd+ Lesion Reduction vs. Placebo	90%	74%
T2 Lesion Reduction vs. Placebo	85% (new or newly enlarging)	71% (new or newly enlarging)
T1 Lesion Reduction vs. Placebo	72% (new)	57% (new)

Data sourced from.[26]

5.2 Moderate-to-Severe Plaque Psoriasis (Skilarence®)

In dermatology, dimethyl fumarate (Skilarence®) is indicated in the European Union for the treatment of adults with moderate-to-severe plaque psoriasis who are in need of systemic medicinal therapy.[4]

5.2.1 The BRIDGE Trial

The cornerstone of evidence for DMF monotherapy in psoriasis is the BRIDGE trial (NCT01726933), a 16-week, Phase 3, randomized, double-blind, multicenter study.[5] This trial had a unique three-arm design, comparing the new DMF monotherapy formulation (Skilarence®) against both placebo and an active comparator, Fumaderm® (the established FAE mixture), in 704 patients.[6]

The co-primary endpoints were the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and the proportion of patients achieving a Physician's Global Assessment (PGA) score of 'clear' (0) or 'almost clear' (1) at week 16.[6]

The results demonstrated both superiority over placebo and non-inferiority to the active comparator:

• Superiority vs. Placebo: A significantly higher proportion of patients treated with DMF achieved PASI 75 (37.5%) compared to those on placebo (15.3%; p<0.001). Similarly, 33.0% of DMF patients achieved a PGA score of 0 or 1, compared to 13.0% of placebo patients (p<0.0001).[4]
• Non-Inferiority vs. Fumaderm®: DMF was shown to be non-inferior to the FAE mixture. The PASI 75 response rate was 37.5% for DMF versus 40.3% for Fumaderm®, and the PGA 0/1 response rate was 33.0% for DMF versus 37.4% for Fumaderm®. Both comparisons met the statistical criteria for non-inferiority (p<0.001 and p<0.0007, respectively).[4] This pivotal finding confirmed that DMF is the main active component and that the additional fumarate salts in Fumaderm® are not necessary for achieving the therapeutic effect in psoriasis.

5.2.2 Long-Term and Real-World Efficacy

The efficacy of fumarates in psoriasis has been shown to increase with longer duration of treatment. The FUTURE study, a large retrospective analysis, found that the proportion of patients rated by physicians as 'markedly improved or clear' increased from 30.8% at 3 months to 67% at 6 months and 76% after one year of FAE therapy.[43]

More recent prospective, non-interventional "real-world" studies, such as SKILL and DIMESKIN, have confirmed the long-term effectiveness and safety of DMF monotherapy (Skilarence®) over 52 weeks of treatment.[44] These studies reported significant and sustained improvements in PASI scores, PGA, and patient-reported quality of life (DLQI). Notably, they also demonstrated positive effects in difficult-to-treat areas such as the scalp, nails, and palmoplantar regions.[45] In the DIMESKIN-2 study, the PASI 75 response rate at 52 weeks was 87.7% among patients who completed the study (observed cases).[44]

Table 3: Summary of the Pivotal Psoriasis Clinical Trial (BRIDGE)

Outcome at Week 16	Dimethyl Fumarate (Skilarence®) (n=267)	Fumaderm® (Active Comparator) (n=273)	Placebo (n=131)
ClinicalTrials.gov ID	NCT01726933	NCT01726933	NCT01726933
% Achieving PASI 75	37.5%	40.3%	15.3%
Statistical Comparison	Superior to Placebo (p<0.001)	-	-
	Non-inferior to Fumaderm® (p<0.001)
% Achieving PGA 'Clear' or 'Almost Clear'	33.0%	37.4%	13.0%
Statistical Comparison	Superior to Placebo (p<0.0001)	-	-
	Non-inferior to Fumaderm® (p<0.0007)

Data sourced from.[4]

6.0 Safety, Tolerability, and Risk Management

The safety profile of dimethyl fumarate is well-characterized and is a critical factor in its clinical management. While the U.S. prescribing information does not contain a boxed warning, it includes several significant warnings and precautions that necessitate diligent patient monitoring.[49] The overall risk-benefit assessment requires balancing its established efficacy against both common, manageable side effects and rare but serious adverse events.

6.1 Common Adverse Events

The most frequently reported adverse events associated with DMF are flushing and gastrointestinal disturbances. These events are most common and severe upon treatment initiation and tend to decrease in frequency and intensity over time.[33]

• Flushing: This is the most common adverse event, affecting up to 40% of patients in MS trials.[15] It is described as a sensation of warmth, redness, itching, and/or burning, typically involving the face, neck, and upper chest.[31] These episodes usually begin soon after taking the medication and resolve within a few hours.[19] Flushing can be managed by administering DMF with food, which slows the absorption and blunts the peak concentration of the active metabolite MMF.[14] Pre-treatment with non-enteric-coated aspirin (up to 325 mg) 30 minutes before dosing has also been shown to reduce the incidence and severity of flushing.[14]
• Gastrointestinal (GI) Events: This category includes diarrhea, nausea, abdominal pain, vomiting, and dyspepsia, and represents the second most common set of side effects.[4] In MS trials, these events were most prominent during the first month of therapy.[33] In psoriasis trials, GI complaints have been reported in up to 60% of patients.[54] Taking the medication with a meal, particularly one containing protein and fat, can help improve GI tolerability.[17]

6.2 Warnings, Precautions, and Serious Adverse Events

While generally manageable, DMF is associated with several rare but serious risks that form the basis of its risk management plan.

• Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, opportunistic viral infection of the brain caused by the reactivation of the John Cunningham (JC) virus. It typically occurs in immunocompromised individuals and is often fatal or results in severe disability.[27] Cases of PML have been reported in patients treated with DMF.[15] The primary identifiable risk factor for developing PML while on DMF is the presence of prolonged moderate to severe lymphopenia (absolute lymphocyte counts <0.8x10⁹/L, and especially <0.5x10⁹/L, persisting for more than six months).[21] Due to this risk, clinicians must withhold DMF at the first sign or symptom suggestive of PML (e.g., progressive weakness, clumsiness, vision changes, cognitive or personality changes) and perform an appropriate diagnostic evaluation, including MRI.[15] The FDA has issued a specific Drug Safety Communication about this risk.[57]
• Lymphopenia: DMF causes a dose-dependent reduction in lymphocyte counts.[2] In MS trials, mean lymphocyte counts decreased by about 30% during the first year of treatment, with 6% of patients on Tecfidera® experiencing severe lymphopenia (<0.5x10⁹/L) compared to less than 1% on placebo.[28] Because lymphopenia is the main risk factor for PML, routine monitoring of blood counts is mandatory. A complete blood count (CBC) with lymphocyte differential is required before initiating therapy, 6 months after starting, and every 6 to 12 months thereafter for MS patients.[28] For psoriasis patients, monitoring every 3 months is recommended.[17] Treatment interruption or discontinuation must be considered if severe lymphopenia persists for more than six months.[21]
• Liver Injury (Hepatotoxicity): Clinically significant cases of drug-induced liver injury have been reported in the postmarketing setting. The onset can range from a few days to several months after starting treatment and can manifest as elevated serum aminotransferases (ALT, AST) and total bilirubin.[2] Baseline and periodic monitoring of liver function tests are required, and DMF should be discontinued if clinically significant liver injury is suspected.[27]
• Anaphylaxis and Angioedema: Serious, potentially life-threatening hypersensitivity reactions can occur after the first dose or at any time during treatment. Signs include difficulty breathing, urticaria (hives), and swelling of the throat and tongue.[2] Anaphylaxis is a contraindication to any future use of the drug.
• Other Serious Infections: Beyond PML, other serious opportunistic infections have been reported, including herpes zoster (shingles), cytomegalovirus, West Nile virus, Aspergillus, Candida, Listeria, and Mycobacterium tuberculosis. These infections can occur in patients with or without lymphopenia.[15]

6.3 Contraindications

The use of dimethyl fumarate is contraindicated in certain situations:

• The universal contraindication across all formulations and regions is known hypersensitivity to dimethyl fumarate or any of the excipients in the formulation.[27]
• The European label for Tecfidera® also lists suspected or confirmed Progressive Multifocal Leukoencephalopathy (PML) as a direct contraindication.[21]
• The European label for Skilarence® includes additional contraindications for patients with severe gastrointestinal disorders, severe hepatic or renal impairment, and during pregnancy and breast-feeding.[16]

Table 4: Summary of Common and Serious Adverse Events with Dimethyl Fumarate

Adverse Event	Frequency Category (MS/Psoriasis)	Description & Clinical Management/Monitoring
Flushing	Very Common (>10%)	Sensation of warmth, redness, itching on face/chest. Manage by taking with food or pre-treating with aspirin. Usually improves over time.
Gastrointestinal Events	Very Common (>10%)	Diarrhea, nausea, abdominal pain, vomiting. Manage by taking with food. Usually most prominent in the first month.
Lymphopenia	Common (1-10%) for moderate; 6% for severe (<0.5x10⁹/L) in MS trials	Reduction in lymphocyte counts. Mandatory monitoring: CBC with differential at baseline, 6 months, then every 6-12 months (MS) or every 3 months (Psoriasis). Consider interruption/discontinuation for prolonged severe lymphopenia.
Liver Injury	Postmarketing reports (Rare)	Elevation of liver enzymes (ALT, AST) and bilirubin. Mandatory monitoring: LFTs at baseline and as clinically indicated. Discontinue if significant drug-induced liver injury is suspected.
Progressive Multifocal Leukoencephalopathy (PML)	Rare	Opportunistic JC virus brain infection, often fatal. Primarily associated with prolonged lymphopenia. Withhold drug and evaluate immediately at first sign/symptom.
Anaphylaxis / Angioedema	Postmarketing reports (Rare)	Severe allergic reaction (hives, swelling of throat/tongue, difficulty breathing). Discontinue immediately and do not restart. This is a contraindication.
Serious Infections	Postmarketing reports (Rare)	Includes herpes zoster (shingles) and other viral, bacterial, and fungal opportunistic infections. Consider withholding treatment until infection resolves.
Serious GI Reactions	Postmarketing reports (Rare)	Includes bleeding, ulcers, perforation, and obstruction. Promptly evaluate new or worsening severe GI symptoms.

Data sourced from.[4]

7.0 Dosing, Administration, and Brand Formulations

Dimethyl fumarate is available globally under different brand names and for different indications, with distinct dosing and administration schedules tailored to each patient population. The formulations are designed as delayed-release or gastro-resistant oral preparations to minimize gastric irritation and optimize delivery to the small intestine.[14]

7.1 Dosing for Multiple Sclerosis (Tecfidera®)

The dosing regimen for relapsing forms of MS is straightforward, involving a short one-week titration period.

• Starting Dose: The initial dose is 120 mg taken orally twice a day for the first 7 days.[15]
• Maintenance Dose: After 7 days, the dose is increased to the standard maintenance dose of 240 mg taken orally twice a day.[15]
• Administration: The delayed-release capsules must be swallowed whole and should not be crushed, chewed, or have their contents sprinkled on food. Tecfidera® can be administered with or without food; however, taking it with food may reduce the incidence of flushing.[14]

7.2 Dosing for Plaque Psoriasis (Skilarence®)

The dosing regimen for moderate-to-severe plaque psoriasis is more complex, featuring a gradual and extended dose-titration schedule designed to maximize tolerability.

• Titration Schedule: Treatment begins with a low dose and is gradually increased over several weeks using both 30 mg and 120 mg gastro-resistant tablets.[16]
• Week 1: 30 mg once daily (in the evening).
• Week 2: 30 mg twice daily.
• Week 3: 30 mg three times daily.
• Week 4 onwards: Treatment switches to 120 mg tablets, starting at 120 mg once daily and increasing weekly by 120 mg increments. The dose is escalated based on individual efficacy and tolerability up to a maximum recommended dose of 720 mg per day (administered as 240 mg three times daily).
• Administration: Skilarence® tablets must be swallowed whole with liquid either during or immediately after a meal to improve gastrointestinal tolerability.[16]

7.3 Brand Names and Generic Formulations

• Tecfidera®: Developed by Biogen, this is the primary global brand name for dimethyl fumarate used in the treatment of MS.[1]
• Skilarence®: Developed by Almirall, this is the brand name for dimethyl fumarate monotherapy used for psoriasis in the European Union.[1]
• Generic Dimethyl Fumarate: Following successful patent litigation, the FDA approved the first generic version of Tecfidera® in the United States in August 2020.[60] Generic formulations are also now available in the European Union, with marketing authorizations granted in April 2024 for products such as Dimethyl Fumarate Accord, Dimethyl Fumarate Mylan, and Dimethyl Fumarate Neuraxpharm, which reference Tecfidera®.[61] The availability of generic versions has significant implications for treatment costs and patient access.

Table 5: Dosing and Administration Summary for MS and Psoriasis

Parameter	Tecfidera® (for Multiple Sclerosis)	Skilarence® (for Plaque Psoriasis)
Indication	Relapsing forms of MS	Moderate-to-severe plaque psoriasis
Starting Dose	120 mg twice daily	30 mg once daily
Titration Schedule	Increase to maintenance dose after 7 days	Gradual weekly increase over 9+ weeks
Maintenance Dose	240 mg twice daily	Individualized, based on response/tolerability
Maximum Dose	480 mg per day (240 mg BID)	720 mg per day (240 mg TID)
Administration with Food	Optional (may reduce flushing)	Mandatory (take with or immediately after a meal)

Data sourced from.[14]

8.0 Comparative Analysis and Place in Therapy

The positioning of dimethyl fumarate in clinical practice is defined by its efficacy and safety relative to other available treatments for multiple sclerosis and psoriasis. While direct head-to-head randomized controlled trials are limited for some comparisons, a substantial body of evidence from indirect analyses, real-world observational studies, and clinical registries helps to delineate its place in therapy.

8.1 Comparison with Other Multiple Sclerosis Therapies

As an oral therapy, DMF offers a significant convenience advantage over older injectable treatments. Its efficacy and safety profile position it as a widely used first- or second-line agent.

• vs. Injectable Therapies (Interferons, Glatiramer Acetate): Real-world evidence from a large French cohort study found that DMF was associated with a significantly lower risk of treated relapses compared to injectable immunomodulators (IMMs), with a relative risk of 0.72.[64] Network meta-analyses of clinical trial data have also suggested that DMF provides a greater reduction in the annualized relapse rate (ARR) compared to various interferon beta formulations.[65] For many patients, the oral route of administration is a decisive factor favoring DMF over daily or weekly injections.[55]
• vs. Other Oral Therapies:
• Teriflunomide (Aubagio®): Comparative effectiveness studies have yielded mixed but informative results. A large prospective observational study (OFSEP) found that DMF and teriflunomide had similar effectiveness on clinical outcomes (relapse rates and disability progression) after two years. However, DMF demonstrated superior efficacy on MRI outcomes (fewer new T2 lesions) and was associated with a lower rate of treatment discontinuation due to lack of effectiveness. Conversely, DMF had a higher rate of discontinuation due to adverse events, primarily flushing and GI issues.[66] Another real-world study found DMF reduced ARR more than teriflunomide (relative risk 0.81).[64]
• Fingolimod (Gilenya®): Real-world data from multiple sources suggest that DMF and fingolimod have broadly similar effectiveness in reducing relapse rates.[41] The choice between them often depends on their differing safety profiles, with fingolimod carrying risks of bradycardia and macular edema, while DMF's primary concerns are lymphopenia and GI/flushing tolerability.
• vs. Non-Specific Immunosuppressants (NSIS): A large international registry analysis (MSBase) compared DMF to older, non-specific immunosuppressants like azathioprine and methotrexate. The study found that while the ARR was similar between the groups, patients on DMF experienced a significantly longer time to treatment discontinuation and a longer time to confirmed disability progression, supporting the use of modern, targeted DMTs like DMF over these older agents.[67]

8.2 Comparison with Other Systemic Psoriasis Therapies

In psoriasis, DMF is positioned as an effective oral systemic therapy, bridging the gap between conventional agents and more potent biologics.

• vs. Conventional Systemics (Methotrexate, Cyclosporine): European treatment guidelines often recommend DMF as a first-line systemic option for long-term use, in part due to its favorable safety profile concerning cumulative organ toxicity compared to agents like methotrexate (liver) and cyclosporine (kidney).[68] Its efficacy is generally considered to be in a similar range to that of methotrexate.[43]
• vs. Biologic Therapies (e.g., Anti-TNFs, Anti-ILs): Biologic agents are generally more effective and have a more rapid onset of action than DMF. Head-to-head clinical trials have demonstrated superior rates of skin clearance (PASI 75) for biologics like the anti-IL-17 agent secukinumab when compared to the FAE mixture.[3] However, a key strength of DMF is its high long-term drug survival rate. Retrospective studies have shown that the proportion of patients remaining on FAE therapy after several years can be higher than that for some anti-TNF biologics, suggesting good long-term tolerability and sustained efficacy in patients who are able to continue treatment.[70]

8.3 Economic and Cost-Effectiveness Analysis

The introduction of oral DMTs for MS, including DMF, came with substantially higher acquisition costs compared to the injectable therapies that preceded them.[72] In 2015, the average annual cost of a newer DMT was approximately $60,000 in the US.[23] Despite its high price, pharmacoeconomic analyses have suggested that DMF is likely to be a cost-effective option compared to fingolimod and glatiramer acetate. These models indicate that by reducing relapses and slowing disability progression, DMF can increase quality-adjusted life years (QALYs) and potentially lower overall lifetime healthcare costs associated with MS management.[74] The advent of lower-cost generic DMF is expected to significantly improve its cost-effectiveness and expand access.[60]

In psoriasis, DMF (Skilarence®) is positioned as a moderately priced oral systemic therapy, with estimated monthly costs ($1,200-$1,500) that are considerably lower than those of biologic agents ($5,000-$7,000 or more).[77] The UK's National Institute for Health and Care Excellence (NICE) has recommended DMF as a cost-effective treatment for severe plaque psoriasis in patients for whom other systemic therapies have failed or are contraindicated.[59]

Table 6: Summary of Comparative Effectiveness of Dimethyl Fumarate

Disease	Comparator Drug(s)	Study Type	Key Efficacy Finding (Relapse/PASI)	Key Safety/Tolerability Finding
Multiple Sclerosis	Injectable DMTs (IFN, GA)	Real-world cohort / NMA	DMF associated with lower relapse rate	Oral route preferred by patients
	Teriflunomide	Real-world cohort	Similar clinical efficacy; DMF superior on MRI outcomes	DMF has higher discontinuation due to AEs; TRF has higher discontinuation due to lack of efficacy
	Fingolimod	Real-world cohort	Similar efficacy on relapse rates	Different safety profiles (DMF: lymphopenia/GI; FTY: cardiac/macular edema)
	Non-Specific Immunosuppressants	Registry analysis	Similar ARR; DMF has longer time to disability progression	DMF has more favorable long-term risk-benefit profile
Psoriasis	Fumaderm® (FAE mixture)	RCT (BRIDGE)	Non-inferior efficacy (PASI 75)	Similar safety and tolerability profiles
	Methotrexate	Guideline comparison	Efficacy considered similar	DMF lacks cumulative organ toxicity risk of MTX
	Biologics (e.g., Secukinumab)	RCT	Biologics show superior and faster skin clearance	DMF has high long-term drug survival rates

Data sourced from.[3]

9.0 Regulatory Landscape

The regulatory history of dimethyl fumarate is notable for its divergent paths in the United States and the European Union, reflecting the different clinical contexts in which the drug was developed and introduced in each region.

9.1 United States (Food and Drug Administration - FDA)

In the United States, the regulatory focus for DMF has been exclusively on its indication for multiple sclerosis.

• Approval of Tecfidera®: Biogen submitted the New Drug Application (NDA 204063) for its DMF formulation, then known as BG-12, in February 2012.[10] Following a priority review, the FDA approved Tecfidera® on March 27, 2013, for the treatment of adults with relapsing forms of multiple sclerosis.[9]
• Post-Marketing Label Updates: Since its approval, the Tecfidera® label has undergone several important revisions to incorporate new safety information gathered from post-marketing surveillance and clinical experience. Significant updates include the addition of warnings regarding the risk of Progressive Multifocal Leukoencephalopathy (PML) in December 2014, as well as warnings for drug-induced liver injury and serious gastrointestinal reactions.[28]
• Generic Approval: The market exclusivity for Tecfidera® was challenged in court. In a pivotal decision, a U.S. federal court invalidated a key patent for the drug, which was originally set to expire in 2028.[60] This ruling opened the door for generic competition much earlier than anticipated. The FDA granted approval for the first generic version of dimethyl fumarate, manufactured by Mylan (now Viatris), on August 17, 2020.[60] This marked the availability of the first oral generic disease-modifying therapy for MS in the United States, a significant event for healthcare economics and patient access.

9.2 European Union (European Medicines Agency - EMA)

In Europe, the regulatory pathway for DMF was influenced by the long-standing use of fumaric acid esters for psoriasis in Germany.

• Approval of Skilarence®: Building on the historical use of Fumaderm®, Almirall developed a monotherapy formulation of DMF. This product, Skilarence®, received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) and was granted marketing authorization by the European Commission on June 23, 2017.[1] Its indication is for the treatment of moderate-to-severe plaque psoriasis in adults. The approval was based on the results of the BRIDGE trial, which established its non-inferiority to Fumaderm®.[5]
• Approval of Tecfidera®: Tecfidera® is also approved in the EU for the treatment of relapsing-remitting MS. The EMA has issued harmonized risk management plans, including specific guidance on monitoring for lymphopenia and the risk of PML.[21]
• Generic Dimethyl Fumarate for MS: Following the expiration of market protection for Tecfidera®, the EMA approved multiple generic versions of dimethyl fumarate for the treatment of RRMS in adults and adolescents from 13 years of age. Marketing authorizations for products including Dimethyl Fumarate Accord, Dimethyl Fumarate Mylan, and Dimethyl Fumarate Neuraxpharm were granted on April 22, 2024.[61]

The different regulatory timelines and indications have led to a divergence in how DMF is perceived and used. In the U.S., it is known almost exclusively as an MS therapy, whereas in Europe, it is an established treatment for both MS and psoriasis. This geographic difference influences physician awareness, prescribing patterns, and market dynamics.

10.0 Conclusion and Future Perspectives

Dimethyl fumarate has successfully transitioned from a component in an empirical herbal-based mixture to a well-defined, evidence-based monotherapy that serves as a cornerstone oral treatment for two distinct chronic autoimmune diseases: relapsing multiple sclerosis and moderate-to-severe plaque psoriasis. Its unique pleiotropic mechanism of action, which synergistically combines Nrf2-mediated antioxidant cytoprotection with NF-κB-mediated immunomodulation, distinguishes it from more narrowly targeted therapies. The clinical efficacy of DMF is robust, supported by large-scale pivotal trials and long-term extension and real-world studies that demonstrate sustained reductions in disease activity and a slowing of disability progression.

The primary challenges associated with its use are rooted in its safety and tolerability profile. The common adverse events of flushing and gastrointestinal distress require proactive patient education and management strategies to ensure adherence, particularly during treatment initiation. More critically, the rare but serious risks of severe lymphopenia, opportunistic infections like Progressive Multifocal Leukoencephalopathy (PML), and drug-induced liver injury mandate strict adherence to recommended monitoring protocols. For appropriately selected and managed patients, the overall benefit-risk profile of dimethyl fumarate is considered favorable.

The journey of dimethyl fumarate exemplifies a cycle of pharmaceutical refinement. Its success and limitations have spurred further innovation, leading to several promising future directions:

• Drug Repurposing: The broad antioxidant and anti-inflammatory effects of DMF make it an attractive candidate for repurposing in other diseases characterized by these pathological processes. Active research and clinical trials are exploring its potential utility in a variety of other conditions, including cardiovascular diseases, respiratory pathologies, certain cancers, and other neurodegenerative disorders like acute ischemic stroke, although not all investigations have been successful.[19]
• Development of Novel Derivatives: To improve upon the benefit-risk profile of DMF, particularly its gastrointestinal tolerability, next-generation fumarate prodrugs have been developed.
• Diroximel fumarate (Vumerity®) is a novel prodrug that is also converted to the active metabolite MMF in the body. It was designed with a distinct chemical structure intended to result in less irritation in the gastrointestinal tract, potentially offering improved GI tolerability compared to DMF.[12]
• To address the issue of skin sensitization which prevents topical use, novel derivatives such as Isosorbide di-(methyl fumarate) (IDMF) are being engineered. These molecules are designed to be less reactive and non-sensitizing, which could unlock the potential for developing a topical fumarate therapy for psoriasis and other inflammatory skin diseases, thereby offering localized treatment without systemic risks.[12]
• Exploration in Other Autoimmune Conditions: The immunomodulatory properties of DMF have led to its investigation in other autoimmune diseases. A Phase 2 clinical trial for its use in Rheumatoid Arthritis has been completed, suggesting its potential applicability may extend even further.[84]

In essence, dimethyl fumarate is not an endpoint but a successful platform. It represents a mature therapeutic modality where the core pharmacology has been validated, and the focus has now shifted to optimizing its delivery, improving its tolerability, and expanding its application, demonstrating a clear trajectory of progressive innovation in medicine.

Works cited

1. Dimethyl fumarate - Wikipedia, accessed August 1, 2025, https://en.wikipedia.org/wiki/Dimethyl_fumarate
2. Dimethyl fumarate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/drugs/DB08908
3. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the ..., accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6060759/
4. Skilarence | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence
5. The European Commission (EC) approves Almirall's Skilarence® for moderate-to-severe chronic plaque Psoriasis, accessed August 1, 2025, https://www.almirall.com/documents/portlet_file_entry/4257831/170627_EC_approves_Almiralls_Skilarence_for_moderate-to-severe_chronic.pdf/999556be-fc27-452b-b56b-fd6fa4663f7d
6. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE) - PubMed, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/27515097/
7. DMF | CAS 624-49-7 | Dimethyl fumarate - Tocris Bioscience, accessed August 1, 2025, https://www.tocris.com/products/dmf_4512
8. Insight into the mechanism of action of dimethyl fumarate in multiple ..., accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/30820593/
9. Dimethyl Fumarat – a New Player in Oral Treatment Options for, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4316891/
10. Tecfidera (dimethyl fumarate) FDA Approval History - Drugs.com, accessed August 1, 2025, https://www.drugs.com/history/tecfidera.html
11. Dimethyl Fumarate | C6H8O4 | CID 637568 - PubChem, accessed August 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dimethyl-Fumarate
12. Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis - PubMed Central, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12051035/
13. Dimethyl Fumarate 624-49-7 | TCI AMERICA, accessed August 1, 2025, https://www.tcichemicals.com/US/en/p/F0069
14. Dimethyl Fumarate: MedlinePlus Drug Information, accessed August 1, 2025, https://medlineplus.gov/druginfo/meds/a613028.html
15. This label may not be the latest approved by FDA. For current ..., accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s029lbl.pdf
16. Skilarence, INN-dimethyl fumarate - European Medicines Agency, accessed August 1, 2025, https://www.ema.europa.eu/en/documents/product-information/skilarence-epar-product-information_en.pdf
17. Skilarence 30 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC) - (emc) | 752, accessed August 1, 2025, https://www.medicines.org.uk/emc/product/752/smpc
18. en.wikipedia.org, accessed August 1, 2025, https://en.wikipedia.org/wiki/Dimethyl_fumarate#:~:text=The%20precise%20mechanism%20of%20action,acid%20receptor%20agonist%20in%20vitro.
19. Novel potential pharmacological applications of dimethyl fumarate—an overview and update - Frontiers, accessed August 1, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1264842/full
20. Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms - PubMed, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/26980071/
21. Tecfidera, INN-dimethyl fumarate - EMA, accessed August 1, 2025, https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf
22. Dimethyl fumarate (CAS 624-49-7) - Cayman Chemical, accessed August 1, 2025, https://www.caymanchem.com/product/14714/dimethyl-fumarate
23. Researchers Reveal Mechanism of Action for Tecfidera, an MS Therapy, accessed August 1, 2025, https://multiplesclerosisnewstoday.com/news-posts/2016/08/12/2016discovered-ms-drug-dimethyl-fumarate-mechanism-of-action/
24. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis, accessed August 1, 2025, https://www.researchwithrutgers.com/en/publications/insight-into-the-mechanism-of-action-of-dimethyl-fumarate-in-mult
25. Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement - Oxford Academic, accessed August 1, 2025, https://academic.oup.com/bjd/article/185/3/605/6599196
26. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis - PubMed Central, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3972027/
27. Tecfidera® (dimethyl fumarate): Official HCP Homepage, accessed August 1, 2025, https://www.tecfiderahcp.com/
28. Reference ID: 4044333 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s017lbl.pdf
29. FAQs | VUMERITY® (diroximel fumarate), accessed August 1, 2025, https://www.vumerityhcp.com/en_us/home/faq.html
30. New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate - MDPI, accessed August 1, 2025, https://www.mdpi.com/1999-4923/14/12/2732
31. Dimethyl fumarate (oral route) - Side effects & dosage - Mayo Clinic, accessed August 1, 2025, https://www.mayoclinic.org/drugs-supplements/dimethyl-fumarate-oral-route/description/drg-20060904
32. Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Pharmacodynamic Effects and Pharmacokinetics In Vivo (P1.207) - Neurology.org, accessed August 1, 2025, https://www.neurology.org/doi/10.1212/WNL.82.10_supplement.P1.207
33. TECFIDERA Label - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf
34. Dimethyl Fumarate | National MS Society, accessed August 1, 2025, https://www.nationalmssociety.org/article/dimethyl-fumarate
35. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/24623127/
36. Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients, accessed August 1, 2025, https://www.mscare.org/data-show-effects-of-tecfidera-in-newly-diagnosed-and-early-disease-course-multiple-sclerosis-patients/
37. TECFIDERA Effectiveness | Tecfidera® (dimethyl fumarate), accessed August 1, 2025, https://www.tecfidera.com/en_us/home/about/benefits.html
38. Dimethyl fumarate Completed Phase 3 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment - DrugBank, accessed August 1, 2025, https://go.drugbank.com/drugs/DB08908/clinical_trials?conditions=DBCOND0036413&phase=3&purpose=treatment&status=completed
39. Cost-effectiveness of dimethyl fumarate (Tecfidera®) for the treatment of adult patients with relapsing remitting multiple sclerosis - National Centre for Pharmacoeconomics, accessed August 1, 2025, https://www.ncpe.ie/wp-content/uploads/2015/01/Dimethyl-Fumarate-Tecfidera-20152-1.pdf
40. BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) - ClinicalTrials.gov, accessed August 1, 2025, https://clinicaltrials.gov/study/NCT00835770
41. TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness - Biogen | Investor Relations, accessed August 1, 2025, https://investors.biogen.com/news-releases/news-release-details/tecfiderar-data-confirm-strong-and-sustained-efficacy-newly
42. The Changing Landscape of Psoriasis: New Horizons for Oral Therapies - EMJ, accessed August 1, 2025, https://www.emjreviews.com/dermatology/symposium/the-changing-landscape-of-psoriasis-new-horizons-for-oral-therapies/
43. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus - ResearchGate, accessed August 1, 2025, https://www.researchgate.net/publication/327807079_Clinical_use_of_dimethyl_fumarate_in_moderate-to-severe_plaque-type_psoriasis_a_European_expert_consensus
44. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study - MDPI, accessed August 1, 2025, https://www.mdpi.com/2077-0383/11/16/4778
45. Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas - PMC - PubMed Central, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8995418/
46. Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis - Radboud Repository, accessed August 1, 2025, https://repository.ubn.ru.nl/bitstream/handle/2066/235283/1/235283.pdf
47. Effect of dimethyl fumarate in patients with plaque psoriasis meeting the upgrade criteria required for moderate‐to‐severe d, accessed August 1, 2025, https://freidok.uni-freiburg.de/files/261488/4TombRkuAmktK5nc/JEADV_Clinical_Practice_2024_Gerdes_Effect.pdf
48. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study - PMC, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9410272/
49. Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis - American Health & Drug Benefits, accessed August 1, 2025, https://www.ahdbonline.com/issues/2014/march-2014-volume-7-special-feature-fifth-annual-payers-guide-to-new-fda-approvals/tecfidera-dimethyl-fumarate-a-new-oral-therapy-approved-by-the-fda-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis
50. full-prescribing-info.pdf - Tecfidera, accessed August 1, 2025, https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf
51. Tecfidera: Side effects and how to manage them - Medical News Today, accessed August 1, 2025, https://www.medicalnewstoday.com/articles/drugs-tecfidera-side-effects
52. Tecfidera (Dimethyl Fumarate): Uses, Side Effects, Dosage - GoodRx, accessed August 1, 2025, https://www.goodrx.com/dimethyl-fumarate/what-is
53. mstrust.org.uk, accessed August 1, 2025, https://mstrust.org.uk/a-z/tecfidera-dimethyl-fumarate
54. Fumaric acid esters - British Association of Dermatologists, accessed August 1, 2025, https://www.bad.org.uk/pils/dimethyl-fumarate/
55. Dimethyl fumarate (Tecfidera) experiences - Symptoms and treatments - MS Society UK, accessed August 1, 2025, https://forum.mssociety.org.uk/t/dimethyl-fumarate-tecfidera-experiences/65523
56. Healthcare Professional Guideline Safety information for Skilarence - HPRA, accessed August 1, 2025, https://assets.hpra.ie/products/Human/10479/494af7ae-02fa-4946-a426-9f42797ce0f8.pdf
57. Tecfidera (dimethyl fumarate) Information - FDA, accessed August 1, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tecfidera-dimethyl-fumarate-information
58. Dimethyl Fumarate: Package Insert / Prescribing Information - Drugs.com, accessed August 1, 2025, https://www.drugs.com/pro/dimethyl-fumarate.html
59. Dimethyl fumarate for treating moderate to severe plaque psoriasis - NICE, accessed August 1, 2025, https://www.nice.org.uk/guidance/ta475/documents/final-appraisal-determination-document
60. FDA Approves Generic Version of Tecfidera®, Taken Orally for MS | MSAA, accessed August 1, 2025, https://mymsaa.org/news/fda-approves-generic-tecfidera
61. Dimethyl fumarate Accord | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-accord
62. Dimethyl fumarate Neuraxpharm | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm
63. Dimethyl fumarate Mylan - EMA Approval - MedPath, accessed August 1, 2025, https://trial.medpath.com/drug/approvals/ema/b9d00346a88a7430
64. (PDF) Comparative effectiveness of dimethyl fumarate in multiple ..., accessed August 1, 2025, https://www.researchgate.net/publication/354501239_Comparative_effectiveness_of_dimethyl_fumarate_in_Multiple_Sclerosis
65. Systematic review and mixed treatment comparison of delayed-release dimethyl fumarate and other disease-modifying therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis (P3.243) - Neurology.org, accessed August 1, 2025, https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P3.243
66. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis, accessed August 1, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000007938
67. Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase - PMC, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11128181/
68. Young Psoriatic Patients Respond Faster to Dimethyl Fumarate: Age-related Differences in Efficacy and Adverse Events, accessed August 1, 2025, https://jcadonline.com/young-psoriatic-patients-dimethyl-fumarate/
69. Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real‐world clinical experience - ResearchGate, accessed August 1, 2025, https://www.researchgate.net/publication/358525392_Efficacy_and_safety_of_Dimethyl_fumarate_in_comparison_with_conventional_therapy_for_psoriasis_an_Italian_real-world_clinical_experience
70. Dimethyl Fumarate in Psoriasis Therapy - European Medical Journal - EMJ, accessed August 1, 2025, https://www.emjreviews.com/dermatology/symposium/dimethyl-fumarate-in-psoriasis-therapy/
71. Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: A prospective single-blinded follow-up study - ResearchGate, accessed August 1, 2025, https://www.researchgate.net/publication/278789369_Long-term_safety_and_effectiveness_of_high-dose_dimethylfumarate_in_the_treatment_of_moderate_to_severe_psoriasis_A_prospective_single-blinded_follow-up_study
72. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4451044/
73. Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018, accessed August 1, 2025, https://www.ahdbonline.com/issues/2020/may-2020-vol-13-no-2/2962-expenditure-utilization-and-cost-of-specialty-drugs-for-multiple-sclerosis-in-the-us-medicaid-population-2008-2018
74. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States - PubMed, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/26707273/
75. Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective | Mantovani | Farmeconomia. Health economics and therapeutic pathways - SEEd's Journals Collection, accessed August 1, 2025, https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1437
76. Dimethyl fumarate Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com, accessed August 1, 2025, https://www.drugs.com/price-guide/dimethyl-fumarate
77. New Psoriasis treatments 2025 - Everyone.org, accessed August 1, 2025, https://everyone.org/explore/treatment/?id=34
78. Drug Approval Package: Brand Name (Generic Name) NDA # - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063orig1s000toc.cfm
79. Tecfidera (dimethyl fumarate) - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204063Orig1s010.pdf
80. Human medicines European public assessment report (EPAR): Dimethyl fumarate Accord, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 2, Status, accessed August 1, 2025, https://efim.org/node/140446
81. Acute Ischemic Stroke Terminated Phase 1 / 2 Trials for Dimethyl fumarate (DB08908), accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0030034/clinical_trials/DB08908?phase=1%2C2&status=terminated
82. Novel potential pharmacological applications of dimethyl fumarate—an overview and update - PubMed Central, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10512734/
83. Tecfidera interactions: Other medications, alcohol, and more, accessed August 1, 2025, https://www.medicalnewstoday.com/articles/drugs-tecfidera-interactions
84. Rhematoid Arthritis Completed Phase 2 Trials for Dimethyl fumarate (DB08908) - DrugBank, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0071364/clinical_trials/DB08908?phase=2&status=completed